Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults

Clinical and Vaccine Immunology

Volumn 16, Issue 7, 2009, Pages 969-977

  Findlow, H ^a   Plikaytis, B D ^b   Aase, A ^c   Bash, M C ^d   Chadha, H ^a   Elie, C ^b   Laher, G ^a   Martinez, J ^b   Herstad, T ^c   Newton, E ^a   Viviani, S ^e   Papaspyridis, C ^a   Kulkarni, P ^f   Wilding, M ^a   Preziosi, M P ^g   Marchetti, E ^e   Hassan King, M ^e   La Force, F M ^e   Carlone, G ^b   Borrow, R ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e PATH   (France)

^f Serum Institute of India   (India)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOGENICITY; INTERMETHOD COMPARISON; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; OPSONIN PROTEINS; PHAGOCYTOSIS; STATISTICS AS TOPIC; VACCINES, COMBINED; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 67650401403     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00068-09     Document Type: Article

References (27)

1. Aase, A., L. M. Næss, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Høiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21:2042-2051. (Pubitemid 36432105)
2. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
3. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal group C conjugate vaccines in the United Kingdom: a reevaluation of correlates of protection. Infect. Immun. 69:1568-1573.
4. Carlone, G. M., C. E. Frasch, G. R. Siber, S. Quataert, L. L. Gheesling, S. H. Turner, B. D. Plikaytis, L. O. Helsel, W. E. DeWitt, W. F. Bibb, B. Swaminathan, G. Arakere, C. Thompson, D. Phipps, D. Madore, and C. Broome. 1992. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:154-159.
5. Findlow, J., S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N. Andrews, R. Barchha, E. Harrison, A. Lowe, E. Boxer, C. Heaton, P. Balmer, E. Kaczmarski, P. Oster, A. Gorringe, R. Borrow, and E. Miller. 2006. Comparison and correlation of Neisseria meningitidis group B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 74:4557-4565.
6. Gheesling, L. L., G. M. Carlone, L. B. Pais, P. F. Holder, S. E. Maslanka, B. D. Plikaytis, M. Achtman, P. Densen, C. E. Frasch, H. Käyhty, J. Mays, L. Nencioni, C. Peeters, D. Phipps, J. Poolman, E. Rosenqvist, G. Siber, B. Thiesen, J. Tai, C. Thompson, P. Vella, and J. Wenger. 1994. Multicenter comparison of Neisseria meningitidis group C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32:1475-1482.
7. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
8. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1348.
9. Gotschlich, E., I. Goldschneider, and M. S. Artenstein. 1969. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129:267-276.
10. Holder, P. K., S. E. Maslanka, L. B. Pais, J. Dykes, B. D. Plikaytis, and G. M. Carlone. 1995. Assignment of Neisseria meningitidis group A and C classspecific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin. Diagn. Lab. Immunol. 2:132-137.
11. Jodar, L., F. M. LaForce, C. Ceccarini, T. Aguado, and D. M. Granoff. 2003. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361:1902-1904. (Pubitemid 36645189)
12. Joseph, H., R. Ryall, M. Bybel, T. Papa, J. MacLennan, J. Buttery, and R. Borrow. 2003. Immunogenicity and immunological priming of the group A portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J. Infect. Dis. 187:1142-1146.
13. Kshirsagar, N., N. Mur, U. Thatte, N. Gogtay, S. Viviani, M. P. Preziosi, C. Elie, H. Findlow, G. Carlone, R. Borrow, V. Parulekar, B. Plikaytis, P. Kulkarni, N. Imbault, and F. M. LaForce. 2007. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 25S:A101-A107. (Pubitemid 47208600)
14. Lal, G., P. Balmer, H. Joseph, M. Dawson, and R. Borrow. 2004. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis groups A, C, Y, and W135. Clin. Diagn. Lab. Immunol. 11:272-279.
15. Lee, C. H., W. C. Kuo, S. Beri, S. Kapre, J. S. Joshi, N. Bouveret, F. M. LaForce, and C. E. Frasch. 2009. Preparation and characterisation of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27:726-732.
16. Lepow, M. L., I. Goldschneider, R. Gold, M. Randolph, and E. C. Gotschlich. 1977. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 60:673-680. (Pubitemid 8242421)
17. Lieberman, J. M., S. S. Chiu, V. K. Wong, S. Partidge, S. J. Chang, C. Y. Chiu, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Safety and immunogenicity of a groups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 275:1499-1503.
18. Makela, H., H. Peltola, H. Kayhty, H. Jousimies, O. Pettay, E. Ruoslahti, A. Sivonen, and O. V. Renkonen. 1977. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J. Infect. Dis. 136:S43-S50.
19. Martinez, J., S. Romero-Steiner, T. Pilishvili, S. Barnard, J. Schinsky, D. Goldblatt, and G. M. Carlone. 1999. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin. Diagn. Lab. Immunol. 6:581-586.
20. Martinez, J., T. Pilishvili, S. Barnard, J. Caba, W. Spear, S. Romero-Steiner, and G. M. Carlone. 2002. Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis group A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity. Clin. Diagn. Lab. Immunol. 9:485-488.
21. Maslanka, S. E., L. Gheesling, D. Libutti, K. Donaldson, H. Harakeh, J. Dykes, F. Arhin, S. Devi, C. E. Frasch, J. Huang, P. Kriz-Kuzemenska, R. Lemmon, M. Lorange, C. Peeters, S. Quataert, J. Tai, G. Carlone, and the Multilaboratory Study Group. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis group A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
22. Norheim, G., A. Aseffa, M. A. Yassin, G. Mengistu, A. Kassu, D. Fikremariam, W. Tamire, Y. Merid, E. A. Hoiby, D. A. Caugant, E. Fritzsonn, T. Tangen, T. Alebel, D. Berhanu, M. Harboe, and E. Rosenqvist. 2007. Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7. Clin. Diagn. Lab. Immunol. 14: 451-463.
23. Peltola, H., H. Makela, H. Kayhty, H. Jousimies, E. Herva, K. Hallstrom, A. Sivonen, O. V. Renkonen, O. Pettay, V. Karanko, P. Ahvonen, and S. Sarna. 1977. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:686-691.
24. Roberts, R. 1970. Relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J. Exp. Med. 131:499-513.
25. Schlesinger, M., R. Greenberg, J. Levy, H. Kayhty, and R. Levy. 1994. Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J. Infect. Dis. 170:449-453.
26. Smith, L. F., and G. H. Lowell. 1980. Antibody-dependent cell-mediated antibacterial activity of human mononuclear cells. II. Immune specificity of antimeningococcal activity. J. Infect. Dis. 141:748-751.
27. World Health Organization. 1976. Requirements for meningococcal polysaccharide vaccine. WHO Tech. Rep. Ser. 588:50-75.